Skip to main content
v2026.11,986 entries · CC-BY 4.0

RARP (CASRAI)

Regulatory Affairs Certification for Research Sites: Professional, RARP (CASRAI)

Applied regulatory affairs for academic sites and sponsor-investigators: IND and IDE decisions, safety reports, Part 54, consent, ClinicalTrials.gov and FDA inspection.

LevelProfessionalRARRARP (CASRAI)
6 h
Nominal
Self-paced study
10
Lessons
Self-paced
8
Domains
Exam blueprint
75
Exam items
Per attempt
70%
Pass mark
Fixed, uncurved
90
Retake wait
Days
3 yr
Valid for
From the pass

What you earn

The credential itself

Pass the examination and CASRAI issues this certificate and the post-nominal RARP (CASRAI), signed by the Programme Director, valid for 3 years, and checkable by anyone from the verification code on its face.

Specimen. Issued as a signed PDF and as a machine-readable Open Badge; the holder and code shown are illustrative.
How it appears on your CV

Certifications

RARP (CASRAI) — Regulatory Affairs for Research Sites, Professional

CASRAI·Issued Mar 2026·Credential ID CASRAI-RAR-2026-RT16JZ

casrai.org/verify/CASRAI-RAR-2026-RT16JZ

Every certificate is issued under the signature of Dr. Diana Nieves Castro, MD, Programme Director of CASRAI Certification, who sets the syllabus, blueprint and pass mark for this credential.

It certifies that its holder passed the CASRAI examination for this course on the date shown, scored against the blueprint and pass mark published on this page — and anyone can confirm it from the verification code, without an account and without contacting us.

About this credential

What it covers

Who this course is for

This is the Professional tier of CASRAI’s Regulatory Affairs for Research Sites programme, leading to the examined credential RARP (CASRAI). It is written for people who hold, or are accountable for, the regulatory position of an academic research site or a sponsor-investigator:

  • regulatory managers and directors in academic clinical trials offices;
  • staff who prepare and maintain INDs and IDEs on behalf of sponsor-investigators;
  • staff and committees who make and document IND-exemption and significant-risk determinations;
  • quality and compliance staff who prepare sites and sponsor-investigators for FDA inspection;
  • ClinicalTrials.gov administrators who manage responsible-party obligations;
  • institutional officials who delegate or supervise regulatory responsibilities.

The course covers US federal rules as they fall on sites and sponsor-investigators: 21 CFR Parts 50, 54, 56, 312 and 812, the Common Rule at 45 CFR part 46, and 42 CFR Part 11 for ClinicalTrials.gov. It assumes working knowledge of the Foundation content and does not teach industry regulatory strategy, marketing applications or global submission planning.

What you will be able to do

  • Write and defend an IND-necessity determination for a study of a marketed drug, addressing each of the five conditions in 21 CFR 312.2(b)(1), and know when to ask FDA for advice under § 312.2(e).
  • Make a significant-risk or non-significant-risk device determination, prepare the explanation to the IRB, and handle an IRB that disagrees.
  • Assemble an IND and an IDE application in the required order, use the sponsor-investigator’s right to refer to a manufacturer’s file, and keep both applications current through amendments, supplements and annual or progress reports.
  • Decide whether an event must be reported, which clock applies and who must receive the report, on both the drug and the device side.
  • Identify the Part 54 clinical investigators on a study, classify their financial interests, and explain why the applicant, not the site, files the forms.
  • Build a consent process that meets FDA rules and, where it also applies, the Common Rule, and advise on continuing review and single-IRB arrangements for multi-site studies.
  • Classify trials as applicable clinical trials, manage responsible-party designations and results deadlines, and explain an institution’s exposure under 42 CFR 11.66.
  • Prepare an expanded access submission, apply FDA’s rules on charging for investigational drugs, and prepare a site and a sponsor-investigator for FDA inspection.

The ten modules

  1. Making and defending the IND determination. The five exemption conditions applied to real study designs, the common shortcuts and why they fail, and how to design an institutional determination process.
  2. Making and defending the risk determination. The significant-risk definition limb by limb, the explanation to the IRB, and what happens when the IRB disagrees.
  3. Building the IND. The eleven parts of an IND in order, how much detail an academic study needs, letters of cross-reference, the seven required protocol elements, and when an investigator’s brochure is required.
  4. Maintaining the IND. Protocol and information amendments, new investigators, the immediate-hazard rule, annual reports and their due dates, clinical holds, inactive status, withdrawal and termination.
  5. Building and maintaining the IDE. The IDE application and investigational plan, when a device study may start, and the three routes for changing an approved plan.
  6. Safety reporting as a submission. The IND safety report threshold, the 7-day and 15-day clocks, device reporting in working days, and separating site duties from sponsor duties when one institution holds both.
  7. Financial disclosure. Who counts as a clinical investigator under Part 54, the four financial interests and their thresholds, covered clinical studies, and the filing chain from site to sponsor to applicant.
  8. Consent, the IRB and multi-site arrangements, applied. FDA and Common Rule consent side by side, continuing review, single-IRB rules and their exceptions, and emergency research under 21 CFR 50.24.
  9. Registration, results and the responsible party. Applicable clinical trial status across a portfolio, designating and withdrawing a principal investigator as responsible party, registration, results and update deadlines, and the consequences of non-compliance.
  10. Meetings, expanded access, inspection and the regulatory file. What 21 CFR 312.47 actually provides, expanded access for individual patients and larger groups, charging for investigational drugs, FDA inspection, disqualification, and running a regulatory file that survives an inspection.

The examination

  • 75 scored multiple-choice questions in each attempt, each with four options and one correct answer. Most are short scenarios that ask you to apply or analyse a rule, not recall it.
  • Questions are drawn from a larger bank in proportion to the eight exam domains below, so two attempts do not show the same set.
  • Pass mark: 70%.
  • You must finish the exam within 4 hours of starting it.
  • If you do not pass, you can sit the exam again after 90 days.
  • You must complete all ten lessons before you can start the exam.
Exam domain Weight Questions per attempt
Determining the regulatory pathway 18% 14
IND preparation, maintenance and lifecycle 16% 12
IDE preparation and the risk determination 13% 10
Safety reporting as a regulatory submission 13% 10
Financial disclosure and investigator conflicts 8% 6
Human-subject protection regulation, applied 12% 9
Registration, results disclosure and transparency 10% 7
Agency interaction, expanded access, inspection and the regulatory file 10% 7

Eligibility

The Foundation tier has no eligibility requirement. The Professional tier is for practitioners with real regulatory responsibility. You qualify through any one of three routes:

  • Experience: 24 months of full-time-equivalent experience in a role carrying regulatory responsibility for clinical research, within the past 6 years.
  • Education plus experience: a completed degree or diploma in a health, life-science, pharmacy, nursing, law or regulatory-science discipline, plus 12 months of that experience.
  • Foundation plus experience: RARF (CASRAI), plus 12 months of that experience.

Regulatory experience means work such as preparing or maintaining an IND or IDE; making, reviewing or documenting IND-exemption or significant-risk determinations; maintaining a site or sponsor regulatory file; collecting and controlling FDA forms and investigator agreements; managing IRB submissions for FDA-regulated research; sponsor-level safety reporting; ClinicalTrials.gov or CTIS responsible-party work; and preparing for or hosting regulatory inspections. Study coordination that includes regulatory binder maintenance counts at half weight. Monitoring, clinical data management and research administration count only for periods in which you also held documented regulatory responsibilities.

At checkout you confirm that you meet one of these routes. CASRAI does not ask for documents at purchase.

What the credential is, and what it is not

RARP (CASRAI) is an examined credential issued by CASRAI. It shows that the holder passed an examination built to a published blueprint, and anyone can verify that it was awarded.

  • It is not accredited by any accreditation body.
  • It carries no CE, CME or CEU credit.
  • It does not satisfy any statutory, regulatory, funder, sponsor, employer or institutional training requirement.
  • It is not endorsed by FDA, any other regulator, any funder or any professional body.
  • It is not the Regulatory Affairs Certification (RAC) offered by the Regulatory Affairs Professionals Society (RAPS), is not equivalent to it and is not a route to it. It is also not the RAPS Foundation in Regulatory Affairs or the RAPS Regulatory Compliance Certification. If your career is in industry regulatory affairs, the RAC is built for that work.
  • It gives the holder no authority to decide that a study is exempt from the IND requirements, that a device is not a significant risk device, or that a trial is not an applicable clinical trial, and no authority to sign Form FDA 1571 or any other document the holder is not otherwise authorised to sign. Those decisions belong to the sponsor, the IRB or FDA under the regulations the course teaches.

Validity and renewal

The credential is valid for 3 years from the date it is awarded. To renew it, pass the current version of the examination again before it expires. Course access does not expire, so you can return to the lessons when you prepare to renew.

Body of knowledge

Exam blueprint

The exam is assembled to these weights on every attempt. They are published before purchase because a blueprint you cannot see is not a blueprint.

Domains and weights8 domains · 75 scored items
DomainWeight
Determining the regulatory pathwayP1
18%14 items
IND preparation, maintenance and lifecycleP2
16%12 items
IDE preparation and the risk determinationP3
13%10 items
Safety reporting as a regulatory submissionP4
13%10 items
Financial disclosure and investigator conflictsP5
8%6 items
Human-subject protection regulation, appliedP6
12%9 items
Registration, results disclosure and transparencyP7
10%7 items
Agency interaction, expanded access, inspection and the regulatory fileP8
10%7 items
Total100%

Every attempt has this many items from each domain. The items themselves are drawn at random from the bank within those fixed per-domain quotas, so no two attempts are the same paper.

Syllabus

Syllabus: 10 lessons, 6 hours

Every lesson and every learning outcome is listed. The lesson bodies open on enrolment, and the exam opens once every lesson is marked complete.

10 lessons · 6.3 h

Lesson material opens once you are enrolled. The full syllabus and every learning outcome are shown here so you can judge the coverage before you pay.

  1. Lesson 1

    Module 1

    1 lesson · 1 h

    1. Locked.Making and defending the IND determination1 h · Locked

      On completion you will be able to

      • Write an IND-necessity determination that addresses each § 312.2(b)(1) condition separately with a stated basis
      • Identify the defect in a determination that relies on § 312.2(d), defensive filing or an IRB decision
      • Decide when a question should go to FDA under § 312.2(e) and draft the request
      • Advise a site on what to do when it disagrees with a sponsor's exemption determination
      • Design an institutional determination procedure and name the record it must produce
  2. Lesson 2

    Module 2

    1 lesson · 30 min

    1. Locked.Making and defending the device risk determination30 min · Locked

      On completion you will be able to

      • State the device characteristic and the serious-risk finding separately for each § 812.3(m) limb
      • Draft the § 812.2(b)(1)(ii) explanation to the IRB for a described device
      • Calculate and assign the § 812.150(b)(9) report when an IRB finds significant risk
      • Explain accurately what § 812.66 and § 812.2(b)(1) each allow FDA and the IRB to do
      • List the Part 812 records and reports an NSR study must still keep
  3. Lesson 3

    Module 3

    1 lesson · 30 min

    1. Locked.Building the IND30 min · Locked

      On completion you will be able to

      • Arrange the contents of an IND in the § 312.23(a) order and justify the detail chosen for each section
      • Determine whether § 312.22(d) relief is available and what written authorisation it needs
      • Draft a protocol that contains each of the seven § 312.23(a)(6)(iii) elements
      • Decide whether an investigator's brochure is required under § 312.55
      • Number a sequence of IND submissions correctly under § 312.23(e)
  4. Lesson 4

    Module 4

    1 lesson · 30 min

    1. Locked.Maintaining the IND30 min · Locked

      On completion you will be able to

      • Classify a proposed change as a new protocol, a protocol change, an information amendment, a new-investigator amendment or none of these
      • Sequence FDA submission and IRB approval correctly for each type of change, including an immediate hazard
      • Calculate an annual report due date from an IND receipt date, with and without a clinical hold
      • Compile the contents of a § 312.33 annual report from a study dataset
      • Describe the effect of a clinical hold and the steps to have it lifted
  5. Lesson 5

    Module 5

    1 lesson · 45 min

    1. Locked.Building and maintaining the IDE45 min · Locked

      On completion you will be able to

      • Assemble an IDE application in the § 812.20(b) order and identify missing elements
      • Draft an investigational plan that meets § 812.25
      • Route a mid-study change through the correct § 812.35 path and state its clock
      • Compare when a study may begin under § 812.30(a) and § 312.40(b)
      • State when treatment use may begin under § 812.36 and what reports follow
  6. Lesson 6

    Module 6

    1 lesson · 30 min

    1. Locked.Safety reporting as a submission30 min · Locked

      On completion you will be able to

      • Apply the three-part § 312.32(c)(1)(i) test to a described event and name any element that fails
      • Calculate the 7-day and 15-day deadlines from given receipt and determination dates
      • List the required recipients of an IND safety report and of a device UADE report
      • Calculate device termination and reporting deadlines in working days
      • Map each safety-reporting duty to a named person where one institution is site and sponsor
  7. Lesson 7

    Module 7

    1 lesson · 30 min

    1. Locked.Financial disclosure under Part 5430 min · Locked

      On completion you will be able to

      • Identify which members of a described study team are Part 54 clinical investigators
      • Classify a described financial arrangement against the four § 54.2 interests and apply any threshold
      • Decide whether a described study is a covered clinical study
      • Explain who files Forms FDA 3454 and 3455 and what the site owes the sponsor
  8. Lesson 8

    Module 8

    1 lesson · 30 min

    1. Locked.Consent, the IRB and multi-site arrangements, applied30 min · Locked

      On completion you will be able to

      • Build a consent document that satisfies both regimes and annotate each element with its source
      • Determine which regime governs a described study and which rule is stricter
      • Advise correctly on continuing review for an FDA-regulated study and for a Common Rule study
      • Advise on whether a described multi-site study needs a single IRB, citing the rule or exception
      • Assemble the procedural steps a § 50.24 study needs before enrolment
  9. Lesson 9

    Module 9

    1 lesson · 45 min

    1. Locked.Registration, results and the responsible party45 min · Locked

      On completion you will be able to

      • Classify a portfolio of studies for applicable-clinical-trial status with a stated basis
      • Carry out a valid principal-investigator designation and recognise when it must be withdrawn
      • Calculate registration, update and results deadlines, including delayed submission and extensions
      • Advise an institution on its exposure under § 11.66
  10. Lesson 10

    Module 10

    1 lesson · 45 min

    1. Locked.Meetings, expanded access, inspection and the regulatory file45 min · Locked

      On completion you will be able to

      • State accurately which meetings § 312.47 provides for
      • Prepare a single-patient expanded access submission and state the physician's sponsor-investigator duties
      • Apply § 312.8 to a charging request in a clinical trial and in expanded access
      • Prepare a site and a sponsor-investigator for an FDA inspection, including record access and retention
      • Describe the disqualification process and who it reaches

Assessment

How the exam works

The exam is closed-book and multiple choice. Each attempt draws a fresh form to the domain weights above, so no two attempts are the same paper and no answer key circulates. The pass mark is 70% and is fixed — there is no curve, no quota and no adjustment by cohort.

Scoring is immediate. Pass, and every item is reviewed with the option you chose, the correct option and its rationale. If you do not pass, you see your overall score and your score per domain (smaller domains are grouped together); which items you missed, and their answers, are held back so your resit is still a real assessment. A failed attempt may be retaken after 90 days. The wait exists so a retake is a second attempt at the material rather than a second attempt at remembering the paper.

The exam opens once you have marked every lesson of the course complete. Forms are assembled to the blueprint above or not at all: where a domain cannot yet be sampled to that standard, the exam declines to start rather than issue an unbalanced paper. Your material and progress are never affected, and there is no time limit on when you sit.

Passing candidates are issued a certificate with a verification code, valid for 3 years from the date of the pass. Anyone can check that code on our public verification page without an account and without contacting us. To renew, pass the current examination again: renewal opens 180 days before the certificate expires, and a pass issues a renewed certificate valid for a further 3 years from that date.

Certifying authority

Signed by Dr. Diana Nieves Castro, MD

CASRAI’s certification programme is academically and medically directed by Dr. Diana Nieves Castro, MD, Programme Director, who sets the syllabus and blueprint for this credential and signs every certificate issued under it.

CASRAI has maintained the terminology and reporting standards of research administration for over a decade. It assumed leadership of the CRediT contributor-roles taxonomy in 2014 and carried it through to adoption as ANSI/NISO Z39.104-2022, now in use by publishers, funders and institutions worldwide. This examination is drawn from that body of work.

What the credential certifies: that its holder passed the CASRAI examination for this course on the date shown, scored against the blueprint and pass mark published above. It is valid for 3 years, and anyone can check it from the verification code on its face.

The ladder

Other levels of Regulatory Affairs for Research Sites

Levels are independent purchases. There is no prerequisite chain — sit whichever level matches the work you already do.

All CASRAI credentials

Common questions

Regulatory Affairs Certification for Research Sites: Professional, RARP (CASRAI): common questions

What is RAC certified?

RAC is the Regulatory Affairs Certification offered by the Regulatory Affairs Professionals Society (RAPS), with separate RAC-Drugs and RAC-Devices exams. RARP (CASRAI) is a different credential that covers the regulatory obligations of academic research sites and sponsor-investigators. It is not the RAC, not equivalent to it, and not issued or endorsed by RAPS, FDA or any other body.

What are the requirements for regulatory affairs certification?

For RARP (CASRAI) you need one of two routes: 24 months of regulatory experience in clinical research in the past 6 years, or 12 months of that experience plus a relevant degree or RARF (CASRAI). You confirm this by ticking a self-attestation checkbox at checkout; there is no separate application or review. You must complete all 10 lessons before you can start the exam.

How much does regulatory affairs certification cost?

RARP (CASRAI) costs US$279, paid once by card through Stripe checkout. Course access does not expire, so you can return to the lessons at any time.

How long does it take to become a regulatory affairs specialist?

There is no single timeline. For this credential, the eligibility routes set the minimum: 24 months of regulatory experience in clinical research, or 12 months plus a relevant degree or RARF (CASRAI). The course itself is 10 lessons and 6 hours of study. The exam has 75 multiple-choice questions with 4 options each, must be finished within 4 hours of starting, needs 70% to pass, and can be retaken after a 90-day wait.

How long is a regulatory affairs certification valid?

The RARP (CASRAI) certificate is valid for 3 years. You renew it by passing the current exam again, and the renewal window opens 180 days before expiry. Each certificate has a public verification page at casrai.org/verify/ followed by its code.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →